CTO Martijn Cox will present data on Xeltis’ novel RestoreX technology on the opening day of the Society For Biomaterials (SFB) Annual Meeting. The data assess the pre-clinical and clinical impact of Xeltis’ medical devices to restore complex heart parts via Endogenous Tissue Restoration (ETR). Xeltis devices are the first to apply state-of-the-art electrospinning technology and bioabsorbable supramolecular polymers to develop heart valves and blood vessels that enable cardiovascular restoration.

The Society for Biomaterials 2017 Annual Meeting is taking place in Minnesota, USA 5-8 April 2017. The meeting focuses on industrial design, fabrication, testing, and translation of biomaterials and this year part of the agenda is focused on “Biomaterials Technology in Industry”.

Xeltis is a clinical-stage company developing synthetic medical devices that enable cardiovascular restoration.